


In the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims

Claim 1 (original): A compound of the formula I:



Formula I

wherein:

Z is selected from N and CH;

W is selected from N and CH;

X is selected from NH and CH₂;

Y is selected from F, Cl, Br and I; and

n is 1, 2 or 3;

and salts or solvates thereof.

Claim 2 (original): A compound of the formula I according to claim 1, wherein Z is N, and salts or solvates thereof.

Claim 3 (currently amended): A compound of the formula I according to claim 1 ~~or claim 2~~, wherein Y is selected from F and/or Cl, and salts or solvates thereof.

Claim 4 (original): A compound of the formula I according to claim 1, selected from one or more of the following:

N-{3-[5-(4-aminothieno[2,3-d]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N'*-(3-fluorophenyl)urea;

N-{3-[5-(4-aminothieno[2,3-d]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-


N^t-(2-fluorophenyl)urea;
N^t{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N*^t-(3-chlorophenyl)urea;
N^t{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N*^t-(2-chlorophenyl)urea;
N^t{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(3-fluorophenyl)acetamide;
N^t{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(2-fluorophenyl)acetamide;
N^t{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(3-chlorophenyl)acetamide;
N^t{3-[5-(4-aminothieno[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2'-(2-chlorophenyl)acetamide;
N^t{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N*^t-(3-fluorophenyl)urea;
N^t{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N*^t-(2-fluorophenyl)urea;
N^t{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N*^t-(3-chlorophenyl)urea;
N^t{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-*N*^t-(2-chlorophenyl)urea;
N^t{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(3-fluorophenyl)acetamide;
N^t{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(2-fluorophenyl)acetamide;
N^t{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(3-chlorophenyl)acetamide;
N^t{3-[5-(4-aminothiazolo[2,3-*d*]pyrimidin-6-yl)-1-methyl-1*H*-imidazol-4-yl]phenyl}-2-(2-chlorophenyl)acetamide;
and salts or solvates thereof.

Claim 5 (currently amended): A pharmaceutical composition comprising a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, as defined in any one of claims 1 to 4 claim 1 in association with a pharmaceutically acceptable diluent or carrier.


Claims 6 – 8 (canceled).

9 (currently amended) A process for preparing a compound of formula I according to claim 1, or a salt or solvate thereof, wherein X is NH and Z, W, Y and n are as defined in formula I claim 1, which process comprises of reacting an amine of the formula II with an isocyanate of the formula III

and thereafter if necessary:



Formula II



Formula III

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) forming a salt or solvate.

10 (new): A method of inhibiting Tie2 receptor tyrosine kinase activity in a warm-blooded animal in need of such treatment, which method comprises administering to said animal an effective amount of a compound of the formula I according to claim 1, or a pharmaceutically acceptable salt or solvate thereof.

11 (new): A method for producing an anti-angiogenic effect in a warm-blooded animal in need of such treatment, which method comprises administering to said animal an effective amount of a compound of the formula I according to claim 1, or a pharmaceutically acceptable salt or solvate thereof.